shutterstock_17556916_-ouh_desire

Ouh Desire / Shutterstock.com

30 September 2019BiotechnologyRichard Wells and Stephanie Pilkington

Dosage patents: Down the hatch

The Supreme Court judgment on March 27, 2019 in Actavis v ICOS UK concerned ICOS’s EP (UK) 1 173 181, exclusively licensed to Eli Lilly, and found it invalid for lack of inventive step in the face of Actavis’, and others’, revocation challenge.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Sandoz wins $137.2m payout for lost profits in generic launch

Dexcom suffers second patent revocation at hands of UPC

Sanofi signs global rights deal to develop rare cancer therapy

Does the UPC offer a fresh take on patent validity?

Litigation implications of the USPTO’s terminal disclaimer proposal

Ipsen files further suit against CSPC over pancreatic cancer drug generic

Federal Circuit denies rehearing in heart valve case

Technical prejudice in support of inventive step: A double-edged sword?